• DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETING
  • MEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHS

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, is pleased to report independent data addressing the frequent question from eyecare practitioners (ECPs) and patients regarding the treatment of meibomian gland disease (MGD) using the TearCare ® System: How long does a new single therapy last?

Clinical outcomes for 78 dry eye patients (156 eyes) treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment associated with MGD using the TearCare ® System and were presented by Thomas Chester, OD, FAAO at the 2022 American Academy regarding Optometry meeting. Patients throughout the study exhibited improved dried out eye signs and symptoms for more than twelve months, and in some cases up to 18 months, post treatment. The study was a retrospective, investigator-initiated trial (IIT) reviewing clinical outcomes with regard to patients who had been treated with the TearCare ® system at least 12 months prior in order to data collection.

“These information showed that patients experienced a 44% decrease in dry out eye symptoms from baseline to week 8, suggesting a fast onset of action from TearCare ® , plus this symptom reduction was maintained through month 13, further recommending sustained long-term improvements associated with the use involving the TearCare ® System. In some patients, these therapeutic benefits were maintained through 1 . 5 years. This info should help provide both patients in addition to practitioners with confidence that some sort of single TearCare ® treatment may improve a good patient’s dried eye signs and symptoms for substantive period of time after the procedure is performed, ” said Thomas Chester, OD, FAAO. “In addition, treatment along with TearCare ® might help address poor patient compliance together with daily prescription eye drop regimens – a common hurdle encountered when doctor prescribed eyedrops are the only treatment option provided. ”

For this study, all patient data were collected from medical records retrospectively with no prospective intervention. Patients’ symptoms were assessed in a single time point pre-treatment and at four time points post-treatment (8-12 weeks, 6 months, a year, and even 18 months). Patients treated with therapies other than TearCare ® within the 12-month window, including ophthalmic prescription medications, were excluded. In total, data from 78 patients (156 eyes) who was simply handled with the particular TearCare ® system and who returned regarding post-treatment follow up were included in the analysis.

Results of typically the trial showed most subjects experienced from least 12 months of gland function improvement and decreased symptoms. Standard Patient Evaluation of Eye Dryness (SPEED) score files decreased approximately 6. 2 points, through 14. 1 ± 6. 5 to be able to 7. 9 ± 5. 7, with eight several weeks after remedy and was maintained up to 12 weeks post-treatment, indicating a positive treatment method outcome. In addition, the average meibomian glandular expression (MGE) score increased 4 points post-treatment coming from baseline connected with 4. nine ± 2 . 6 in the right eye and 4. 8 ± 2. four in this left eye to 9. 0 ± second . 7 (P < 0. 001) within the right eye together with 9. 0 ± 2. 9 (P< 0. 001) in the left eye (measured at 8 weeks post-treatment) and remained at least 3 factors higher by baseline over the course of a year with your month 10 score with 7. eight ± one. 7 (P < 0. 001) in the correct eye and additionally 7. 8 ± 1 . 4 (P < 0. 001) within the left eye, again indicating positive cure outcomes in the signs for dry vision.

“Sight Sciences is committed to redefining the treatment paradigm intended for dry vision, a disease that will until now has primarily been treated by prescription eye drops not to mention artificial tears, ” said Paul Badawi, CEO about Sight Savoir. “Considering just approximately 5% of dried up eye individuals currently receive interventional MGD procedures such as TearCare ® for often the treatment of their dry attention just one , we believe these types of clinical records demonstrate your durability in treatment effect with TearCare ® and will support greater adoption of the procedure. Interventional procedures for dry up eye not only address the often mismatched mechanism of actions of commonly prescribed Rx that typically target aqueous deficiency when most dry eye patients are suffering from accelerated tear evaporation due for you to MGD 2 but they also help tackle patient compliance issues and the high monthly costs from daily prescription drugs. Since the exact use of the TearCare ® System helps address the root underlying cause of obstructive MGD and evaporative dry eyesight, and since our growing body associated with clinical data files suggest that such use confers durable efficacy advantages for many patients, all of us believe it will change how free of moisture eye will be treated in the future. ”

Our objective is that these extensive efficacy findings, along using the ongoing prospective SAHARA RCT (NCT04795752) directly comparing the TearCare ® system having Restasis within the first ever large-scale device versus drug RCT, will provide payors with evidence in support of insurance coverage for TearCare ® along by using a provider reimbursement pathway.

References:

  1. Market Scope 2021: Ocular Surface Illness Survey
  2. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in some clinic-based individual cohort: a fabulous retrospective study. Cornea. 2012; 31(5): 472-478. doi: 10. 1097/ICO. 0b013e318225415a

About Sight Sciences

View Sciences is an eyecare technology organization focused on developing and also commercializing innovative solutions intended to convert care as well as improve patients’ lives. Using minimally invasive or non-invasive approaches to help target the particular underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The particular Company’s OMNI ® Surgical System is an important minimally intrusive glaucoma surgery (MIGS) gadget indicated to reduce intraocular pressure in adult patients through primary open-angle glaucoma (POAG), the planets leading cause of irreversible blindness. The SION™ Surgical Instrument is a bladeless, manually operated system used inside ophthalmic surgical procedures to excise trabecular meshwork. Typically the Company’s TearCare ® System will be 510(k) cleared in the United States to get the application of localized heat therapy found in adult individuals with evaporative dry attention disease due to meibomian sweat gland dysfunction (MGD), enabling office-based clearance regarding gland obstructions by physicians to tackle the leading cause of dry eye illness.

About the TearCare ® Program

This TearCare ® System is FDA removed and indicated for typically the using localized heat therapy in grownup patients utilizing evaporative waterless eye condition because of meibomian gland dysfunction, when used in conjunction with manual expression from the meibomian glands. The TearCare ® System is usually the only unit designed to evacuate obstructed meibomian glands while harnessing the natural blink experience. The system is comprised of single-use, universally fitting SmartLids™ which are placed on the eyelids to deliver “intelligent therapeutic heat” safely and effectively. The portable SmartHub™ communicates directly with the help of the SmartLids to precisely control the amount of phase transition heating as well as the duration involving treatment. After 15 minutes of therapeutic heat, this Clearance Assistant forceps allows the ECP to control expression of the stagnant, obstructed meibum expertly and precisely simply by targeting individual meibomian intrigue while obtaining full visual confirmation connected with the success of this particular personalized therapy.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by often the Company, contains certain forward-looking statements inside the meaning of Section 27A from the Securities Act of 1933, as amended, and Area 21E of the Securities Exchange Act with 1934, as amended. The Company intends this kind of forward-looking claims to be covered by your safe harbor provisions pertaining to forward-looking assertions contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these kinds of safe possess provisions. Any statements made in this specific press release or during the earnings call that are not transactions of historical fact, which includes statements about our beliefs and expectations, are forward-looking statements and should be evaluated as these kinds of. Forward-looking phrases include info concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These records often include words this sort of as “anticipate, ” “expect, ” “suggests, ” “plan, ” “believe, ” “intend, ” “estimates, ” “targets, ” “projects, ” “should, ” “could, ” “would, ” “may, ” “will, ” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we all have made in light of our experience in the industry, as well as our own perceptions for historical trends, current conditions, expected future developments and other factors many of us believe are appropriate under the exact circumstances on such period. Although most of us believe that all these forward-looking statements are based on reasonable assumptions during the moment they are produced, you should be aware of which many factors could affect our business, results about operations plus financial condition in addition to could trigger actual results to differ materially from those expressed in the forward-looking arguments. These statements are not really guarantees in future performance or results. The forward-looking statements are usually subject to and even involve risks, uncertainties together with assumptions, and additionally you should not place undue reliance on these kind of forward-looking terms. These forward-looking statements consist of, but are not limited to, statements concerning the following: estimates of the total addressable market, future revenue, expenses, capital requirements, and each of our needs meant for additional financing; our ability to enter into and compete in new markets; execution in our market strategies; the impact from the COVID-19 pandemic on our business, all of our customers’ not to mention suppliers’ businesses and the particular general economy; our ability to contend effectively with existing competitors and brand new market entrants; our capability to scale your infrastructure; some of our ability in order to manage and also grow this business by simply expanding our sales to be able to existing customers or introducing our products to fresh customers; our own ability for you to establish as well as maintain intellectual property protection for the products or avoid claims of infringement; potential effects of extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances designed for our items that assistance our revenue projections, company strategies plus growth; each of our ability to help successfully execute our medical trial roadmap; our capability to acquire and maintain sufficient reimbursement for our goods; our capabilities to protect in addition to scale all of our intellectual property portfolio; your ability to hire and retain key personnel; our capacity to get financing in future offerings; the volatility of typically the trading price of some of our common stock; our expectation regarding this time throughout which we will be an emerging growth company under often the Jumpstart Our own Business Startups Act (the “JOBS Act”); our potential to sustain proper and even effective internal controls; and the other important factors discussed under the caption “Risk Factors” in our filings with the U. S. Securities together with Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statement should not necessarily be construed by you to be exhaustive and usually are made simply as of your date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a new result associated with new details, future events or otherwise, except as required by applicable law.

Media Contact
Hannah Jenkins
RHMM Inc.
903. 340. 4278
[email protected] com

Investor contact
Philip Taylor
Gilmartin Group
415. 937. 5406
Investor. [email protected] com


Primary Logo

Leave a Reply

Your email address will not be published. Required fields are marked *